The Health Risks Of Winter Storms
Extreme weather can have deadly consequences, as evidenced by the recent winter storm that swept across the United States. At least 30 deaths were attributed to the weekend’s snowstorm, with forecasters warning that frigid temperatures could persist for weeks in many areas. The storm dumped more than a foot of snow in at least 19 states, including Texas and Tennessee, leading to widespread power outages affecting nearly 400,000 people.
One of the lesser-known risks associated with winter storms is the physical strain of shoveling snow. A 2020 report by the American Heart Association identified shoveling as a strenuous activity that can put significant stress on the heart. The combination of physical exertion and cold temperatures can lead to increased heart rate and blood pressure, making it a potentially dangerous activity for individuals, especially those with underlying health conditions.
In the world of pharmaceuticals, Korean company Sam Chun Dang Pharm has seen a surge in investor optimism following the development of a new weight-loss pill. The company’s chairman, Yoon Dae-in, has become a billionaire as a result of the pill’s success, with Forbes estimating his net worth at $2.1 billion. Sam Chun Dang recently signed an agreement with Japanese drug maker Daiichi Sankyo to jointly develop and commercialize the weight-loss pill, entering a competitive market dominated by major players like Lilly and Novo Nordisk.
Meanwhile, in the realm of biotech, Mendra, a new startup founded by veterans of BioMarin Pharmaceuticals, has raised $82 million to utilize artificial intelligence in the development of therapies for rare diseases. Led by OrbiMed, 8VC, and 5AM Ventures, Mendra aims to streamline the drug development process and bring treatments to market more efficiently. The company’s CEO, Joshua Grass, brings a wealth of experience from his time at BioMarin and other biotechs, positioning Mendra as a promising player in the biotech landscape.
On the technology front, OpenEvidence founder Daniel Nadler has seen his wealth soar to $7.6 billion following a successful $250 million fundraising round. OpenEvidence’s AI-based search tool has revolutionized the way doctors access and analyze clinical information, making it a valuable resource for healthcare professionals. With a rapidly growing user base and a valuation of $12 billion, OpenEvidence is poised to make a significant impact in the healthcare sector.
As the healthcare industry continues to evolve, innovative technologies and treatments are paving the way for improved patient care and outcomes. From the development of cutting-edge pharmaceuticals to the use of artificial intelligence in drug discovery, the future of healthcare looks promising. Stay tuned for more updates and insights on the latest trends and developments in the world of healthcare and biotech.
